The sharp difference in clinical outcome observed in surgically resected patients with high levels of SerpinB3, but different extent of p66shc expression in tumoral tissue, has potentially interesting implications for management of patients with HCC, since different therapeutic approaches could be proposed based on the expression pattern of the two molecules. This evidence concerns the gene SERPINB3 and hepatocellular carcinoma.